Beam Therapeutics gets buy rating from JonesTrading with $35 target price
BEAM•JonesTrading assumed coverage of Beam Therapeutics with a buy rating and a $35 target price.
Related News
Acacia Research Corporation Q3 revenue $54.445 million
ACTG•
Shake Shack Q3 net income jumps 30% to $17.77 million; revenue rises 15% to $423.27 million
SHAK•
Chimera Investment posts wider Q3 loss as market volatility weighs
CIM•
Regenxbio Q3 operating expenses USD 44.696 million
RGNX•
Real REMAX Group Q3 EPS was USD -2.25
REAX•